Abstract
Polyene macrolide amphotericin B (AmB) is the drug of choice for the treatment of disseminated fungal infections. However, because of its pronounced side effects, the drug has limited applicability. There are few interesting reports, which state that co-administration of the drug with homo-peptide of polyaspartic acid reduces the side effects of the drug. In our present study, an approach has been made to systematically synthesize low molecular weight heteropeptides consisting ofl-aspartic acid and its derivative. It was hypothesized that such heteropeptides will reduce the toxic side effects of the drug by facile hydrophobic binding between the polymer and the drug. We have employed the strategy of solid phase peptide synthesis (SPPS) to synthesize low molecular weight hetero-peptides by usingl-aspartic acid and benzyl-l-aspartic acid to induce the hydrophobic binding between the peptide and the drug. In future, the proposed methodology can be employed to tailor other polypeptides substituted with benzyl groups to reduce the nephrotoxicity of AmB.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berman, J. D., Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.Clin. Infect. Dis., 24, 684–703 (1997).
Bodey, G. P., Anaissie, E. J., Elting, L. S., Estey, E., O'Brien, S., and Kantarjian, H., Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B.Cancer, 73, 2099–2106 (1994).
Borowski, E., Novel approaches in the rational design of antifungal agents of low toxicity.Farmaco, 55, 206–208 (2000).
Brajtburg, J., Powderly, W. G., Kobayashi, G. S., and Madoff, G., Amphotericin B: delivery systems.Antimicrob. Agents Chemother., 34, 381–384 (1990).
Branch, R. A., Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation.Arch. Intern. Med., 148, 2389–2394 (1988).
Brime, B., Molero, G., Frutos, P., and Frutos, G., Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans.Eur. J. Pharm. Sci., 22, 451–458 (2004).
Carpino, L. A. and Han, G. Y., 9-Fluorenylmethoxycarbonyl amino-protecting group.J. Org. Chem., 37, 3404–3409 (1972).
Chemushevich, I. V., Loboda, A. V., and Thomson, B. A., An introduction to quadrupole-time-of-flight mass spectrometry.J. Mass Spectrom., 36, 849–865 (2001).
Kaloyanides, G. J., Antibiotic-related nephrotoxicity.Nephrol. Dial. Transplant., 9 (suppl 4), 130–134 (1994).
Kishore, B. K., Kallay Z, Lambricht P, Laurent G, and Tulkens P. M., Mechanism of protection afforded by polyaspartic acid against gentamycin-induced phospholipidosis I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layersin vitro.J. Pharmacol. Exp. Ther., 255, 867–874 (1990a).
Kishore, B. K., Lambricht, P., Laurent, G., Maldague, P., Wagner, R., and Tulkens, P. M., Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis II. Comparativein vitro andin vivo studies with poly-l-aspartic, poly-l-glutamic, and poly-d-glutamic acids.J. Pharmacol. Exp. Ther., 255, 875–885 (1990b).
Mann, M., Hendrickson, R. C., and Pandey, A., Analysis of proteins and proteomes by mass spectrometry.Annu. Rev. Biochem., 70, 437–473 (2001).
Merrifield, R. B., Solid phase peptide synthesis: the synthesis of a tetrapeptide.J. Am. Chem. Soc., 85, 2149–2154 (1963).
Meyer, R. D., Young, L. S., Armstrong, D., and Yu, B., Aspergillosis complicating neoplastic disease.Am. J. Med., 54, 6–15 (1973).
Miranda, L. P. and Alewood, P. F., Accelerated chemical synthesis of peptides and small proteins.Proc. Natl. Acad. Sci. U.S.A., 96, 1181–1186 (1999).
Mullen, A. B., Carter, K. C., and Baillie, A. J., Comparison of the efficacies of various formations of amphotericin B against murine visceral leishmaniasis.Antimicrob. Agents Chemother., 41, 2089–2092 (1997).
Saxena, S. and Ghosh, P. C., Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice.Pharm. Res., 17, 1236–1242 (2000).
Sheppard, R. C., Modern methods of solid-phase peptide synthesis.Science Tools, 33, 122–129 (1986).
Townsend, R. W., Zutshi, A., and Bekersky, I., Biodistribution of 4-[(14) C] cholesterol-Ambisome following a single intravenous administration to rats.Drug Metb. Dispos., 29. 681–685 (2001).
Wamock, D. W., Amphotericin B: an introduction.J. Antimicrob. Chemother., 28(Suppl. B), 27–38 (1991).
Wiebe, V. J. and DeGregorio, M. W., Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.Rev. Infect. Dis., 10, 1097–1101 (1988).
Whitelegge, J. P., Gundersen, C. B., and Faull, K. E., Electrospray-ionization mass spectrometry of intact intrinsic membrane proteins.Protein Science, 7, 1423–1430 (1998).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoo, B.K., Jalil Miah, M.A., Lee, ES. et al. Synthesis of decapeptide ofl-aspartic acid and benzyl-l-aspartic acid by solid phase peptide synthesis. Arch Pharm Res 28, 756–760 (2005). https://doi.org/10.1007/BF02977338
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02977338